News of Celladon Corp.'s possible liquidation after the CUPID2 phase IIb failure in April of gene therapy candidate Mydicar for heart failure (HF) may have sent shivers through the gene therapy sector, but progress ought to provide a heartening counterbalance as researchers continue to refine their methods.